Plus Therapeutics provides business update on CNSide Diagnostics subsidiary

Plus Therapeutics (PSTV) will provide a business update for its wholly-owned subsidiary, CNSide Diagnostics. The proprietary CNSide Cerebrospinal Fluid, CSF, Assay Platform is designed and intended for patients suspected of having central nervous system cancer metastases, CNS Mets. The first test to be commercialized, CNSide CSF Tumor Cell Enumeration, TCE, has a total addressable market estimated to be $6 billion in the U.S. “The developer of the CNSide technology invested over $300 million in this core technology and after a year of detailed analysis and preparation by our team and key consultants, our enthusiasm regarding the unmet clinical need and the inherent value of CNSide has only grown,” said Marc H. Hedrick, M.D., Plus Therapeutics’ President and Chief Executive Officer.